Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy

25 Jan 2024

Abstract excerpt

We investigated whether we could identify a panel of miRNAs associated with response to treatment in tumor tissues of patients with Hormone Receptor-positive/HER2-negative metastatic breast cancer treated with endocrine therapy (ET) and the CDK4/6 inhibitor (CDK4/6i)i palbociclib. In total, 52 patients were evaluated, with 41 receiving treatment as the first line. The overall median PFS was 20.8 months (range...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38338777
DOI: 10.3390/ijms25031498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine TherapyPMID 38338777Read ↗

Comparative biomarker analysis of PALOMA-2/3 trials for palbociclibSemantic proximity Read ↗

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read ↗

Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA ExplorationSemantic proximity Read ↗

Prognostic Role of Tumor Subtype and Germline BRCA Mutation in Advanced Breast Cancer Patients Treated with Palbociclib Plus Endocrine TherapySemantic proximity Read ↗

Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast CancersSemantic proximity Read ↗

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+ MCF7 Breast Cancer CellsSemantic proximity Read ↗

Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast CancerSemantic proximity Read ↗

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast CancerSemantic proximity Read ↗

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancerSemantic proximity Read ↗

Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.Semantic proximity Read ↗

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity Read ↗

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.